ANIPANI Pharmaceuticals, Inc.
$73.92-24% 1Y
$73.92
$70.1652 weeks$95.93
The financials
ANI Pharmaceuticals, Inc. by the numbers
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $266M in Q2 2026 (quarter ended Jun 30, 2026), up 26% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $25M (9.3% of revenue). For the full year FY2025, revenue was $883M (+44% year on year) and net income $78M. Its largest product in Q2 2026 was Total Sales Of Generics And Other at $101M, 39.4% of the disclosed total, just ahead of Sales Of Generic Pharmaceutical Products at 38.8%. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $266M | $211M | +26% |
| Gross profit | $166M | $137M | +21% |
| Operating income | $40M | $14M | +191% |
| Net income | $25M | $8.5M | +189% |
| Diluted EPS | $1.05 | $0.36 | +192% |
| Product | Revenue | Share |
|---|---|---|
| Total Sales Of Generics And Other | $101M | 39% |
| Sales Of Generic Pharmaceutical Products | $99M | 39% |
| Sales Of ILUVIEN And YUTIQ | $19M | 7.3% |
| Sales Of Established Brand Royalties And Other | $18M | 6.9% |
| Sales Of Established Brands | $12M | 4.6% |
| Unapproved Products | $5.7M | 2.2% |
| Sales Of Generic Other | $1.6M | 0.6% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $255.3M (-8.1%)
Sales Of Generic Pharmaceutical Products grew +9.7% year on yearSales Of Generic Other -59% year on year
Segment Latestquarter on quarteryear on year
- Total Sales Of Generics And Other$100.7M$100.7Mquarter on quarter -7.8%year on year +6.8%-7.8%+6.8%
- Sales Of Generic Pharmaceutical Products$99.1M$99.1Mquarter on quarter -6.0%year on year +9.7%-6.0%+9.7%
- Sales Of ILUVIEN And YUTIQ$18.7M$18.7Mquarter on quarter -2.8%year on year -16%-2.8%-16%
- Sales Of Established Brand Royalties And Other$17.7M$17.7Mquarter on quarter -18%year on year n/a-18%n/a
- Sales Of Established Brands$11.8M$11.8Mquarter on quarter -4.2%year on year -10%-4.2%-10%
- Unapproved Products$5.7M$5.7Mquarter on quarter -9.5%year on year -6.6%-9.5%-6.6%
- Sales Of Generic Other$1.6M$1.6Mquarter on quarter -58%year on year -59%-58%-59%
Drug Manufacturers, Specialty & Generic
Ranks #9 of 41 by RyuScore